Home / Solutions

解决方案

Solutions

South Korea has developed a sensor to diagnose severe Alzheimer's disease

Date:2020-12-23 15:07:37

Number of readers:   

Recently, Samsung Electronics announced that the Samsung health monitoring application has been certified by the Korean Ministry of Food and Drug Safety (MFDS) as a medical machine software. In this regard, TaeJong Jay Yang, senior vice president of Samsung Electronics and head of the health team of the mobile communications business, said that the Samsung health monitoring application combines Samsung’s first-class hardware and the latest software innovations, which can effectively help millions of patients with hypertension worldwide .

It is reported that this application combined with the advanced sensor technology on the Galaxy Watch Active 2 allows users to measure and track their blood pressure more conveniently. Galaxy Watch Active2 measures blood pressure through pulse wave analysis, which is tracked by a heart rate monitoring sensor. Then, the program analyzes the relationship between the calibration value and the blood pressure change to determine the blood pressure. To ensure accuracy, the user must calibrate the device at least once every four weeks.
In addition to blood pressure monitoring, Galaxy Watch Active2 also has Samsung's most advanced health and wellness functions to date. Galaxy Watch Active2 is equipped with a more sensitive and accurate heart rate monitoring sensor, allowing users to track their exercise, sleep and stress.
 
Samsung said that this health monitoring application will be launched on the Galaxy Watch Active2 in the third quarter and will gradually expand to the upcoming Galaxy Watch devices.
 
Further reading: South Korea has developed a sensor to diagnose severe Alzheimer's disease
 
A few days ago, the Korean Academy of Science and Technology research team developed a sensor that can diagnose severe Alzheimer's disease. Alzheimer's disease is a neurodegenerative disease that causes dementia, which mainly affects the elderly. According to statistics, 10% of the world’s elderly population over 65 suffer from the disease. Although equipment such as positron emission computed tomography (PET) and nuclear magnetic resonance imaging (NMRI) can be used to diagnose Alzheimer's disease, the cost of diagnosis is relatively expensive, and it is cheap to develop and accurately diagnose Alzheimer's disease The equipment becomes a top priority.
After adjusting the pressure of nanoparticles on the surface of the solution, the research team developed a high-density carbon nanotube array diagnostic sensor using tomography technology that can be freely aligned. The sensor successfully developed this time has a sensitivity 100 times higher than the existing biosensor based on carbon nanotubes. Using this sensor, the concentration of biomarkers can be determined on blood samples from patients with Alzheimer's disease, with a sensitivity of 90% and an accuracy of 88.6%.